Overview

Calidi Biotherapeutics Inc. (NYSE American: CLDI) announced new pre‑clinical data for its lead oncolytic‑virus asset CLD‑401 at the American Association of Cancer Research (AACR) annual meeting held in San Diego on 21 April 2026. The presentation was followed by several press releases and secondary coverage on the same day and the previous day.

Key Findings from the AACR Presentation

  • Asset: CLD‑401, a systemically delivered oncolytic virus engineered to express high levels of IL‑15 superagonist (IL‑15 SA) within the tumor microenvironment (TME).
  • Platform: RedTail, a virotherapy platform that selectively targets tumors, remodels the TME, and delivers therapeutic genetic payloads directly inside the tumor after systemic administration.
  • Pre‑clinical results:
  • Profound immune activation in the TME, including recruitment and activation of natural killer (NK), NK‑T, and γδ T‑cells.
  • Robust therapeutic response observed in immunocompetent animal models.
  • Safety profile: High IL‑15 SA expression in the TME with low circulating levels, suggesting an expanded therapeutic window.
  • Future plans: Filing an Investigational New Drug (IND) application for CLD‑401 by the end of 2026, with clinical entry anticipated shortly thereafter.

Additional Platform Developments

  • The RedTail platform also supports in‑situ expression of tumor‑targeted T‑cell engagers, as demonstrated in a separate AACR presentation focused on CLD‑501.
  • Calidi continues to pursue strategic partnerships to accelerate clinical development and broaden the impact of the RedTail platform.

Market and Regulatory Context

  • Lock‑up agreement: Certain representative warrants of Calidi were subject to a lock‑up agreement that ends on 21 April 2026, potentially impacting post‑announcement trading activity.
  • Stock performance: As of 19 April 2026, the closing price of CLDI was $0.2502. The 52‑week high and low are $19.20 and $0.209, respectively, indicating significant volatility.
  • Company fundamentals: Market capitalization is $3,040,000. The price‑earnings ratio is –0.04, reflecting its clinical‑stage status.

Media Coverage

The data presentation was reported by multiple outlets on 21 April 2026, including Globenewswire, Marketscreener, Feedburner, and Investing.com. The coverage highlighted the potential of CLD‑401 to reshape the therapeutic landscape for solid tumors through targeted genetic medicine.

Conclusion

Calidi Biotherapeutics’ latest pre‑clinical results for CLD‑401 demonstrate promising immunogenic activity within the tumor microenvironment, supporting the company’s strategy to advance the RedTail platform toward clinical development. The scheduled IND filing by the end of 2026 will mark a significant milestone in Calidi’s effort to deliver systemic, tumor‑restricted virotherapy to patients with solid tumors.